Payment overview · 2025
General Payments
$335.37
19 reported records · 10 companies
Healthcare provider profile · identity verified
Melissa Dawn Graves, MD
Allopathic & Osteopathic Physicians|Family Medicine · KEYSER, WV · NPI 1891907549
Verified facts
What the public records show
CMS Open Payments records show Melissa Dawn Graves, MD received $335.37 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.16 | 26.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.86 | 24.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.06 | 10.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.92 | 6.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.46 | 6.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.64 | 6.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.21 | 5.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.60 | 4.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.39 | 4.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.07 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $335.37 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.65 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.65 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $60.03 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 63 |
| Omeprazole | Omeprazole | 242 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 46 |
| Lisinopril | Lisinopril | 182 | 48 |
| Losartan Potassium | Losartan Potassium | 181 | 41 |
| Gabapentin | Gabapentin | 124 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 29 |
| Furosemide | Furosemide | 108 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 33 |
| Metformin Hcl Er | Metformin Hcl | 101 | 29 |
| Alprazolam | Alprazolam | 100 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 21 |
| Sertraline Hcl | Sertraline Hcl | 81 | 24 |
| Lorazepam | Lorazepam | 78 | 17 |
| Metformin Hcl | Metformin Hcl | 78 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 23 |
| Simvastatin | Simvastatin | 72 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 21 |
| Tramadol Hcl | Tramadol Hcl | 67 | suppressed |
| Eliquis | Apixaban | 65 | 17 |
| Enalapril Maleate | Enalapril Maleate | 56 | 15 |
| Montelukast Sodium | Montelukast Sodium | 56 | 14 |
| Ozempic | Semaglutide | 56 | 17 |
| Ondansetron Odt | Ondansetron | 55 | 13 |
| Ibuprofen | Ibuprofen | 54 | 17 |
| Carvedilol | Carvedilol | 51 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 16 |
| Lovastatin | Lovastatin | 51 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 12 |
| Trazodone Hcl | Trazodone Hcl | 47 | 11 |
| Atenolol | Atenolol | 45 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | 11 |
| Celecoxib | Celecoxib | 44 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Allopurinol | Allopurinol | 43 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 12 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 18 |
| Glipizide Er | Glipizide | 36 | 12 |
| Prednisone | Prednisone | 36 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.37 · 19 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPVAXIVE, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Jornay PM, Kerendia, Ozempic, ROTATEQ, Rybelsus, The Cologuard Plus Collection Kit, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error